ICON Public (NASDAQ:ICLR) Given New $290.00 Price Target at Citigroup

ICON Public (NASDAQ:ICLR) had its target price cut by investment analysts at Citigroup from $300.00 to $290.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. Citigroup’s target price points to a potential upside of 30.29% from the stock’s current price.

Several other equities research analysts also recently commented on the stock. Redburn Atlantic began coverage on shares of ICON Public in a research note on Monday, October 14th. They issued a “neutral” rating and a $311.00 target price on the stock. Truist Financial reaffirmed a “buy” rating and set a $284.00 price objective (down from $295.00) on shares of ICON Public in a research note on Wednesday, December 18th. Evercore ISI cut their target price on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Baird R W lowered ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Finally, Leerink Partnrs upgraded ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Stock Performance

NASDAQ:ICLR opened at $222.58 on Monday. The firm has a market capitalization of $18.36 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 1.54 and a beta of 1.20. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a 12-month low of $183.38 and a 12-month high of $347.72. The firm has a 50-day moving average price of $211.60 and a 200 day moving average price of $273.51.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The company had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $3.10 earnings per share. Research analysts anticipate that ICON Public will post 13.42 earnings per share for the current fiscal year.

Institutional Trading of ICON Public

Several institutional investors and hedge funds have recently made changes to their positions in the business. Foyston Gordon & Payne Inc acquired a new stake in shares of ICON Public during the third quarter worth $11,672,000. Icon Wealth Advisors LLC increased its stake in shares of ICON Public by 861.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after acquiring an additional 11,840 shares during the last quarter. Sara Bay Financial acquired a new stake in shares of ICON Public in the 3rd quarter valued at approximately $1,143,000. Whittier Trust Co. boosted its stake in ICON Public by 12.3% during the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock worth $1,155,000 after acquiring an additional 441 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new position in ICON Public during the second quarter valued at approximately $54,000. Institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.